[Clinical profile of patients with secondary immunodeficiency on immunoglobulin replacement therapy].

Alicia Méndez-Gómez, Noemí Gómez-Hernández, Margarita Ortega-Cisneros, Bricia Melissa Gutiérrez-Zepeda, Antonio de Jesús Quintero-Rodríguez, Luis Alberto Duran-Marín, Marya Lizzeth Rosaldo-Solís, Antonio Quintero-Ramos
{"title":"[Clinical profile of patients with secondary immunodeficiency on immunoglobulin replacement therapy].","authors":"Alicia Méndez-Gómez, Noemí Gómez-Hernández, Margarita Ortega-Cisneros, Bricia Melissa Gutiérrez-Zepeda, Antonio de Jesús Quintero-Rodríguez, Luis Alberto Duran-Marín, Marya Lizzeth Rosaldo-Solís, Antonio Quintero-Ramos","doi":"10.5281/zenodo.19099403","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Secondary immunodeficiency (SID) is a disorder in which the immune system is compromised by external or acquired factors, reducing the quantity or function of immunoglobulins. This condition increases the need for specialist consultation, follow-up, and replacement therapy, which in turn raises healthcare costs. To date, few studies have clinically characterized patients with SID; therefore, understanding their profile will enable improved management and treatment.</p><p><strong>Objective: </strong>To describe the clinical profile of patients with SID receiving human immunoglobulin replacement therapy (IgG-RT).</p><p><strong>Material and methods: </strong>A retrospective observational study was conducted through the review of 40 medical records of patients with SID undergoing IgG-RT. Risk factors and the benefits of replacement therapy were analyzed.</p><p><strong>Results: </strong>The mean age was 48 years, with a predominance of women (62.5%). The most frequent conditions were rheumatologic diseases (38%), followed by hematologic disorders (31%) and protein-losing diseases (27%). All patients had received corticosteroids in combination with another immunosuppressant, and 77.5% had also been treated with rituximab. Infections were recorded in 50% of cases; however, only 35% received prophylaxis. Relapse was documented in 22.5% of patients, and mortality was 2.5%.</p><p><strong>Conclusions: </strong>The use of corticosteroids and immunosuppressants, specifically rituximab, was the main cause of SID, predominantly associated with rheumatologic and hematologic diseases.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":"64 Suppl 1","pages":"e6671"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268660/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.19099403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Secondary immunodeficiency (SID) is a disorder in which the immune system is compromised by external or acquired factors, reducing the quantity or function of immunoglobulins. This condition increases the need for specialist consultation, follow-up, and replacement therapy, which in turn raises healthcare costs. To date, few studies have clinically characterized patients with SID; therefore, understanding their profile will enable improved management and treatment.

Objective: To describe the clinical profile of patients with SID receiving human immunoglobulin replacement therapy (IgG-RT).

Material and methods: A retrospective observational study was conducted through the review of 40 medical records of patients with SID undergoing IgG-RT. Risk factors and the benefits of replacement therapy were analyzed.

Results: The mean age was 48 years, with a predominance of women (62.5%). The most frequent conditions were rheumatologic diseases (38%), followed by hematologic disorders (31%) and protein-losing diseases (27%). All patients had received corticosteroids in combination with another immunosuppressant, and 77.5% had also been treated with rituximab. Infections were recorded in 50% of cases; however, only 35% received prophylaxis. Relapse was documented in 22.5% of patients, and mortality was 2.5%.

Conclusions: The use of corticosteroids and immunosuppressants, specifically rituximab, was the main cause of SID, predominantly associated with rheumatologic and hematologic diseases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
【继发性免疫缺陷患者免疫球蛋白替代治疗的临床概况】。
背景:继发性免疫缺陷(SID)是一种免疫系统受到外部或后天因素损害,导致免疫球蛋白数量或功能降低的疾病。这种情况增加了对专家咨询、随访和替代治疗的需求,这反过来又增加了医疗保健费用。迄今为止,很少有研究具有SID患者的临床特征;因此,了解它们的特征将有助于改进管理和治疗。目的:描述SID患者接受人免疫球蛋白替代治疗(IgG-RT)的临床概况。材料和方法:回顾40例SID患者接受IgG-RT治疗的病历,进行回顾性观察性研究。分析了替代治疗的危险因素和益处。结果:平均年龄48岁,以女性居多(62.5%)。最常见的疾病是风湿病(38%),其次是血液病(31%)和蛋白质流失疾病(27%)。所有患者均接受了皮质类固醇联合另一种免疫抑制剂,77.5%的患者也接受了利妥昔单抗治疗。50%的病例有感染记录;然而,只有35%的人接受了预防。22.5%的患者复发,死亡率为2.5%。结论:皮质类固醇和免疫抑制剂的使用,特别是利妥昔单抗,是SID的主要原因,主要与风湿病和血液病相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Sleep disorders associated with montelukast in children with respiratory allergy]. [Artificial intelligence and cardiovascular biobanks: Shared technological promise and ethical responsibility]. [Acute pancreatitis as first manifestation of systemic lupus erythematosus]. [Association between anthropometric clinical predictors and HOMA-IR]. [Anomalous origin of the right pulmonary artery: Non-invasive diagnosis and early surgery].
wanfang
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1